These findings indicate that high IL7R expression promotes p-STAT1 activation, driving cisplatin resistance and migration in p53R175G cells, while IL7R pharmacological inhibition markedly suppresses tumor progression and enhances the efficacy of cisplatin treatment. This evidence concerns the gene STAT1 and neoplasm.